Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer

Trial Profile

Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Jun 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.
    • 25 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 10 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top